Water Vapor Ablation for Prostate Cancer: Long-Term Registry

The purpose of the registry is to evaluate real-world safety, efficacy, and patient reported outcomes among participants receiving Vanquish Water Vapor Ablation System therapy (Vanquish Therapy). This includes longitudinal assessment of patients who have received or will receive the therapy one or multiple times as part of routine clinical care and encompasses those who completed a company-sponsored Vanquish therapy study (as applicable).

NCT Number	NCT07455058
Lead Sponsor	Francis Medical Inc.
Conditions	Prostate Cancer
Enrollment	2,500 participants
Start Date	2026-06-05
Primary Completion	2041-04-30 (estimated)
Study Completion	2041-07-31 (estimated)
Updated on ClinicalTrials.gov	2026-06-12